Login / Signup

A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01.

Shinji AtagiTakashi DaimonKyoichi OkishioKiyoshi KomutaYoshio OkanoKoichi MinatoYoung Hak KimRyo UsuiChiharu TabataAtsuhisa TamuraMasaaki Kawahara
Published in: Thoracic cancer (2023)
The prematurely terminated study did not show the benefit of two cytotoxic agents over single-agent therapy for previously treated NSCLC patients.
Keyphrases
  • phase iii
  • end stage renal disease
  • small cell lung cancer
  • chronic kidney disease
  • ejection fraction
  • squamous cell carcinoma
  • mass spectrometry
  • prognostic factors
  • radiation therapy
  • peritoneal dialysis
  • rectal cancer